SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4237:45AM Neurogen announces results of first-in-human trial for insomnia drug (NRGJim Oravetz-9/22/2005
422NRGN announces results of P1 for insomnia drug: >>BRANFORD, Conn., Sept. tuck-9/22/2005
421Neurogen Corp 2Q Losses 26c/Shr Vs 13c DOW JONES NEWSWIRES August 4, 2005 7:41 aJim Oravetz-8/4/2005
420v3.espacenet.com it's actually WO02008221, with a S.I. biofreak as inventorscaram(o)uche-6/12/2005
419They gave the wrong number. You leave off the "A1", as that's thescaram(o)uche-6/12/2005
418IP for VR1 antagonists (follow-up of previous post): appft1.uspto.gov Abbott tuck-6/12/2005
417Other VR1 antagonist programs coming out of the woodwork. Makes me wonder what tuck-6/12/2005
416fellow from needham noted the next data point is not until year end, so you are mopgcw-5/31/2005
415rkrw, Apparently rnvs disclosed some additional cerovive data over the weekend.keokalani'nui-5/31/2005
414Comparison NRGN to RNVS deal. Fairly comparable. Upfront nrgn $30M (even splitrkrw-5/31/2005
413Competing VR1 program from Renovis, just licensed to Pfizer: Message 21372786 tuck-5/31/2005
412It may be, but it is way early for any serious concern. MiljenkoMiljenko Zuanic-3/26/2005
411[AMG 9810, a Novel VR1 Antagonist with Antihyperalgesic Properties] >>J Ptuck-3/26/2005
410[Immunological role of neuronal receptor VR1 expressed on DCs] >>Publishetuck-3/26/2005
409Neurogen Announces Phase I Clinical Trial for Proprietary Insomnia Drug BRANFORJim Oravetz-12/21/2004
408Sounds like a good deal to me. Do you know why the stock is up 10% today? I didnMadharry-11/22/2004
407Neurogen to Assume Rights Under CRF-1 Collaboration Wednesday September 15, 4:51keokalani'nui-9/15/2004
406I have 34M s/o. They're trying to pry their sleep cpd back from pfe. Not rkrw-8/5/2004
405The last flurry of activity here was mid-June. Along with others, Wilder commenJohn Metcalf-8/5/2004
404Neurogen Corporation Announces Second Quarter 2004 Financial 2004-08-04 07:33 (Nmopgcw-8/4/2004
403Stock was at $9.30 when I commented on MC. Cash was 3/31, but obviously I must keokalani'nui-6/16/2004
402<<But $318m market cap, $60m cash>> I have a $260M market cap (@7.6rkrw-6/16/2004
401Market being very kind. Not that remaining programs are not very good but they keokalani'nui-6/16/2004
400Short-term perhaps? BVF and Merck involvement supporting?mopgcw-6/16/2004
399Maybe! Stock is now on priority screen, and in time I may (will) increase my poMiljenko Zuanic-6/16/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News